Clinical Research Directory
Browse clinical research sites, groups, and studies.
ENX-205 SAD/PET Study in Healthy Adults
Sponsor: Engrail Therapeutics INC
Summary
This is a two-part study designed to evaluate the safety, tolerability, pharmacokinetics (PK), and receptor occupancy (RO) of ENX-205 in healthy adult participants in a double-blind placebo-controlled, single ascending dose (SAD) study (Part 1) and an open-label, single-dose, positron emission tomography (PET) study (Part 2).
Official title: A Two-Part, Single Ascending Dose and Positron Emission Tomography Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Receptor Occupancy After Single Oral Dose Administration of ENX-205 in Healthy Adult Participants
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2025-03-23
Completion Date
2026-04
Last Updated
2026-03-11
Healthy Volunteers
Yes
Conditions
Interventions
ENX-205
oral solution
Placebo
oral solution
Locations (1)
Parexel London EPCU
London, Middlesex, United Kingdom